Indian pharmaceutical giant Cipla has entered into a strategic agreement with US-based Eli Lilly to market tirzepatide, the active ingredient in the widely acclaimed weight-loss drug Mounjaro, in India. The announcement, made on Thursday, marks a significant step in addressing the growing demand for effective weight management solutions in the country. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has gained global recognition for its efficacy in weight reduction and diabetes management. This collaboration leverages Cipla’s extensive distribution network and Eli Lilly’s innovative pharmaceutical expertise, aiming to make the drug accessible to a broader population in India. The move comes amid rising concerns over obesity and related health issues in the region, highlighting the potential impact of this partnership on public health. Both companies expressed optimism about the initiative, emphasizing their commitment to improving healthcare outcomes through advanced medical solutions.